{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-088195","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.844103+00:00","generated_at":"2026-05-15T22:17:43.642189+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enliven reports Q4/FY2025 results; initial Phase 1b data for ELVN-001 shows MMR rates 47-69%","bullets":["Net loss of $29.7M for Q4 2025 vs $23.2M for Q4 2024; full year net loss $103.7M vs $89.0M.","Cash, equivalents and marketable securities $462.6M, providing runway into first half of 2029.","Initial Phase 1b data: MMR achieved in 47% (80 mg QD) and 69% (60/120 mg QD) of evaluable patients.","Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected to initiate in second half of 2026.","Rick Fair appointed CEO in December 2025; Scott Garland added to board in January 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-088195","json":"https://secwatch.observer/filing/0001193125-26-088195.json","markdown":"https://secwatch.observer/filing/0001193125-26-088195.md","text":"https://secwatch.observer/filing/0001193125-26-088195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/0001193125-26-088195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/elvn-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:17:43.642189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}